BRANFORD, Conn., Jan. 12, 2015 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) (CASMED), a leader in medical devices for non-invasive patient monitoring, announces the engagement of Deltex Medical Group plc (AIM:DEMG) as the exclusive distributor of CASMED's FORE-SIGHT line of cerebral oximeter monitors for the United Kingdom and Ireland. The engagement of Deltex is effective as of January 1, 2015.
"Deltex Medical and CASMED have a shared commitment to Level 1 scientific evidence and its role in sales, marketing, and patient care. Using this approach, Deltex has become the leader in hemodynamic monitoring across the U.K., and we look forward to their past success benefiting our FORE-SIGHT cerebral oximeter monitors in the licensed geographies," said Thomas M. Patton, President and Chief Executive Officer of CASMED. "With a sales channel to over 90% of major U.K. hospitals and a team of expert clinical support personnel, Deltex is well positioned to penetrate the market with FORE-SIGHT oximetry."
Founded in 1992 with headquarters in Chichester, West Sussex, Deltex Medical manufactures fluid management devices including the CardioQ-EDM™ and the CardioQ-EDM+™ esophageal Doppler monitor. With the goal of making esophageal Doppler monitoring (EDM) a standard-of-care, more than 3,000 CardioQ-EDM systems are currently in use in hospitals worldwide with more than 40,000 disposable surgical probes used in the U.K. alone each year. Deltex Medical has been awarded a National Institute for Health & Care Excellence (NICE) recommendation for the CardioQ-EDM, and EDM fluid management has been identified as one of six high-impact innovations across the National Health Service based on comprehensive evidence that proves it can reduce postoperative complications and reduce the length of hospital stays.
"The FORE-SIGHT ELITE®oximeter provides another innovative and useful product for Deltex's established distribution organization to sell to the exact same customers that they work with every day," Mr. Patton continued. "We also look forward to expanding the application of tissue oximetry into additional patient applications where the control of hemodynamic instability and cerebral perfusion can improve patient care."
About Deltex Medical
Deltex Medical manufactures and markets CardioQ-EDM™ oesophageal Doppler monitoring systems. EDM is the only therapy to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up, and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow, and measures them immediately. Randomized controlled trials using Doppler have demonstrated that early fluid management intervention can reduce postoperative complications, reduce intensive care admissions, and reduce the length of hospital stay. The CardioQ-EDM has two distinct established clinical applications, including to guide fluid management during surgery and to monitor cardiac output in critical care settings. For more information regarding Deltex Medical, visit the Company's website at www.deltexmedical.com.
About CASMED® – Monitoring What's Vital
CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT® Absolute Cerebral Oximeter provides a highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care. For more information regarding CASMED, visit the Company's website at www.casmed.com.
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Company's Form 10-K for the year ended December 31, 2013, and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.
CAS Medical Systems, Inc.
Jeffery A. Baird
Chief Financial Officer
Source:CAS Medical Systems, Inc.